Stress-adaptation in obesity-associated pancreatic cancer

肥胖相关胰腺癌的压力适应

基本信息

  • 批准号:
    10415876
  • 负责人:
  • 金额:
    $ 35.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT Obesity increases the risk for pancreatic ductal adenocarcinoma (PDA) by ~ 50% and mortality by more than 2-fold. Strikingly, PDA has the highest death rate among the most commonly diagnosed cancers, and with a rising occurrence, it is predicted to become the 2nd leading cause of cancer deaths by 2020. The mechanisms through which obesity promotes PDA are not well understood; however, the prevailing paradigm is that obesity-associated stress and inflammatory markers play an essential role. Accordingly, stress stimuli (hypoxia, oxidative-, nutrient-, biomechanical-stress, etc.) are thought to invoke the engagement of stress- adaptive strategies by cancer cells to enhance their fitness. We have recently demonstrated that non- membranous organelles termed stress granules, are a novel stress-coping machinery that is mobilized by KRAS mutant PDA cells under stress to enhance tumor fitness and survival. Our preliminary data provide the first lines of evidence indicating that stress granules are essential to the development of obesity-associated PDA, and identified insulin growth factor-1 (IGF-1), a principal mediator of obesity-driven cancer, as a potent inducer of stress granules. The goal of this proposal is to elucidate the mechanisms by which stress granules promote obesity-associated PDA and to develop anti-stress granule chemopreventive approaches. We propose to: 1) determine the role of IGF-1 in stress granule upregulation in obesity-associated PDA, 2) decipher how stress granules promote obesity-associated PDA, and 3) target stress granules for the chemoprevention of obesity-associated PDA. Collectively, these studies can establish stress granules as a novel mechanism through which obesity promotes stress adaptation and PDA development, and inform the development of new chemopreventive strategies.
摘要 肥胖使胰腺导管腺癌(PDA)的风险增加约50%,死亡率增加超过10%。 2倍。值得注意的是,PDA在最常见的癌症中死亡率最高, 发病率上升,预计到2020年将成为癌症死亡的第二大原因。的机制 肥胖促进PDA的机制尚不清楚;然而,流行的范式是, 肥胖相关的压力和炎症标记物起着重要作用。因此,压力刺激 (缺氧、氧化应激、营养应激、生物力学应激等)被认为是引发了压力的作用 癌细胞的适应性策略来增强它们的适应性。我们最近发现,非... 被称为应激颗粒的膜性细胞器是一种新型的应激应对机制, KRAS突变PDA细胞在应激下增强肿瘤适应性和存活。我们的初步数据提供了 第一批证据表明,压力颗粒是必不可少的发展肥胖相关的 PDA,并确定胰岛素生长因子-1(IGF-1),肥胖驱动的癌症的主要介质,作为一种有效的 应激颗粒诱导剂。该建议的目的是阐明应激颗粒 促进肥胖相关的PDA和开发抗应激颗粒化学预防方法。我们 建议:1)确定IGF-1在肥胖相关PDA中应激颗粒上调中的作用,2) 破译压力颗粒如何促进肥胖相关的PDA,和3)针对压力颗粒, 肥胖相关PDA的化学预防。总的来说,这些研究可以建立应力颗粒作为 肥胖促进压力适应和PDA发展的新机制,并为研究提供信息 开发新的化学预防策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elda Grabocka其他文献

Elda Grabocka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elda Grabocka', 18)}}的其他基金

Stress adaptation in obesity-associated pancreatic cancer
肥胖相关胰腺癌的压力适应
  • 批准号:
    10581170
  • 财政年份:
    2023
  • 资助金额:
    $ 35.69万
  • 项目类别:
Stress-adaptation in obesity-associated pancreatic cancer
肥胖相关胰腺癌的压力适应
  • 批准号:
    9577297
  • 财政年份:
    2018
  • 资助金额:
    $ 35.69万
  • 项目类别:
Stress-adaptation in obesity-associated pancreatic cancer
肥胖相关胰腺癌的压力适应
  • 批准号:
    10183195
  • 财政年份:
    2018
  • 资助金额:
    $ 35.69万
  • 项目类别:
Exploriing the role of oncogenic Ras in stress response mechanisms
探索致癌 Ras 在应激反应机制中的作用
  • 批准号:
    7753725
  • 财政年份:
    2009
  • 资助金额:
    $ 35.69万
  • 项目类别:
Exploriing the role of oncogenic Ras in stress response mechanisms
探索致癌 Ras 在应激反应机制中的作用
  • 批准号:
    7936093
  • 财政年份:
    2009
  • 资助金额:
    $ 35.69万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 35.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 35.69万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 35.69万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 35.69万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 35.69万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 35.69万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 35.69万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 35.69万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 35.69万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 35.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了